2017 年 43 巻 11 号 p. 648-653
The administration of tazobactam/piperacillin (TAZ/PIPC) to patients with renal failure requires dose reduction since it is eliminated through the kidneys. Therefore, we set TAZ/PIPC dose reduction criteria for the administration of TAZ/PIPC to renal failure patients; in addition, the pharmacist checked renal function and dose for proper use. We investigated the influence of the rate of renal failure patients administered TAZ/PIPC on antimicrobial use density (AUD), days of therapy (DOT), and AUD/DOT.
The rate of the number of patients administered TAZ/PIPC with renal failure, the rate of TAZ/PIPC dose and dosing days were calculated, and these variables were determined for each month of the study period. Furthermore, we assessed the correlations of AUD, DOT, AUD/DOT with the patient rate, dose rate and dosing days rate for each month. As a result, AUD/DOT was significantly and negatively correlated with patient rate (r = -0.634, P = 0.027), dose rate (r = -0.783, P = 0.003), and dosing days rate (r = -0.695, P = 0.012).
AUD/DOT is an indicator of the one-day dosing of antimicrobials. TAZ/PIPC one-day dose was correlated with renal function in 84.4％ of cases owing to the dose reduction criteria and checked by the pharmacist in this study. This suggests that the dose of TAZ/PIPC was appropriately adjusted based on renal function. We found that as the rate of administration of TAZ/PIPC, eliminated through the kidneys, in patients with renal failure increased, AUD/DOT decreased. Our findings support the appropriate assessment of antimicrobial dosage surveillance.
